Check Your Email to Confirm
We’ve sent you a confirmation link — check your inbox and click it to activate your subscription.
Once confirmed, you’ll get notified when we publish new research. We publish infrequently, only when we have something worth saying.
In the meantime, browse our research or explore the intelligence platform.
Specialist Fund Concentration in DMD Treatments: Pipeline and Mechanisms
Duchenne muscular dystrophy has attracted an unusual concentration of specialist biotech hedge fund interest. We mapped interventional trials across 10 companies and overlaid beneficial ownership data from 18 specialist funds to show where that consensus sits and why.
Read analysis →
Baker Brothers Renewed Their Acadia Exit Infrastructure
Baker Bros filed Schedule 13D Amendment 17 on Acadia showing a renegotiated registration rights agreement allowing block trades. We pulled 14 years of Baker's 13D filing history to see what this could mean.
Read analysis →